Portfolio

	Atherotech Atherotech is a medical diagnostic and testing company. The company's proprietary, highly accurate VAP cholesterol test is rapidly becoming the medical standard for routine cholesterol testing.
	Behavioral Health Systems Behavioral Health Systems is a specialty healthcare company that provides behavioral and mental health services nationally.
	Cumberland Pharmaceuticals Cumberland Pharmaceuticals is a specialty pharmaceutical company. The company acquires and develops branded prescription products primarily in the gastroenterology, critical care and infection control areas.
	TransMolecular TransMolecular is a neuroscience therapeutics company discovering and developing novel, proprietary drugs to diagnose and treat cancer and pain.
	Tranzyme Tranzyme Pharma is a clinical-stage company developing novel small molecule therapeutics for the treatment of gastrointestinal (GI) and metabolic diseases.
	Vaxin Vaxin is a therapeutic vaccine company focused on generating an immune response through non-invasive means. The company's “EasyVax” needleless immunization technology is utilized therapeutically and preventatively in the areas of infectious disease, bioterrorism and cancer.
	Applied Genomics Applied Genomics, Inc. develops targeted genomics-based diagnostic and therapeutic antibodies for the treatment of cancer.
	FoodSource Lures FoodSource Lures developed the world's first and only molded fishing lures made entirely out of edible ingredients. There is also a drug delivery application embedded within the FoodSource product development strategy. The Company is jointly developing an oral rabies vaccine bait for wildlife with MERIAL, Ltd. Other products are under consideration such as an edible carrier for oral medicines for cattle and other livestock as well as a bait for administering oral contraceptives to control deer populations. MERIAL is a joint venture of Merck and Sanofi-Avertis, two of the world's largest pharmaceutical companies.
	Genaco Genaco Biomedical Products, Inc. (Genaco) is a post-genomic era biotechnology platform company, utilizing the information and technologies derived from the Human Genome Project (HGP) to develop molecular differential diagnostics (MDD).
	CardioSpectra, Inc CardioSpectra, Inc. is a medical device company committed to developing novel solutions for worldwide healthcare problems through the implementation of its expertise in optical imaging, interventional cardiology, medical devices, and materials science. Through its Optical Coherence Tomography (OCT) technology, CardioSpectra is developing products that address the early detection of vulnerable plaque; glaucoma; macular degeneration; diabetic retinopathy; and cancer. No existing or identified emerging technology, other than OCT, has the capability to definitively diagnose vulnerable plaque. For this reason, CardioSpectra’s primary research focus centers around this lead product opportunity.
	Vidacare Corporation Vidacare is a company that owns the exclusive rights to innovative intraosseous technology and is leading the development of medical devices that greatly improves the ability of emergency health professionals to administer life saving drugs and fluids in both the pre-hospital and hospital situations.
	Expression Genetics, Inc. Expression Genetics is focused on developing therapeutics for the treatment of human diseases including cancer and cardiovascular disease. The company specializes in the delivery of therapeutic nucleic acides (DNA and RNAi) and proteins aimed at specific disease targest via its proprietary TheraPlas technology.
	BioDtech, Inc. BioDtech, Inc. markets and develops products for the detection, neutralization and removal of biological toxins for pharmaceutical manufacturing and clinical applications.
	PNP Therapeutics, Inc. PNP Therapeutics, Inc. was founded to fully exploit the cancer curing potential of the E.coli enzyme, purine nucleoside phosphorylase (PNP). The Company is dedicated to the successful development and commercialization of a unique suicide gene therapy approach that is predicated on the knowledge that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.
	Discovery BioMed, LLC Discovery BioMed, LLC seeks to conribute to improvements in human health through its expertise, work, and facilities by: providing partners and clients with pilot screening and high-throughput screening (HTS) services for therapeutic-related bioassays, providing partners and clients with custom immortalized cell lines, and performing therapeutics discovery for certain failure-to-secrete diseases in humans.
	Aeon BioScience, Inc. Aeon BioScience, Inc. is a collaborative venture involving Brookwood Pharmaceuticals, Inc., Targeted Technology Ventures, LLC and the Birmingham Technology Fund - partners that have extensive experience in drug delivery and medical polymer formulation, device commercialization, and in the capitalization of innovative medical technologies, respectively. The company will work to develop a new drug-eluting stent, the goal of which will be to overcome the current concerns of late stent thrombosis, or blood clot formation at or near the site of the stent and vessel closure due to formation of scar tissue, known as restinosis.
	Halo Research, Inc. Halo Research is a technical healthcare product company focused on developing wearable biomedical systems for health and lifestyle monitoring. Halo's products are positioned to address healthcare concerns for a large and growing population of independently living elderly adults. Unlike the majority of competing products which require seniors to manually press a panic button, Halo's products can automatically detect serious health concerns - even a user falling - without any active participation from the user, and remotely notify designated caregivers. The product includes wireless wearable technology for monitoring physiological signals, a wireless gateway for encrypting and transmitting physiological data to a secure health server, and a web-based interface to facilitate continuous and remote monitoring from anywhere in the world, anytime of day.
	VectorLogics, Inc. VectorLogics (VLI) is a biotechnology company focused on the development and commercialization of virus based cancer therapies and therapeutic vaccines for viral liver diseases. VLI is focused on developing products for the treatment of cancer and liver diseases using attenuated viral delivery systems. The cancer products are highly selective (recongizing cancer cells - avoiding normal cells) and highly specific (active in cancer cells - inactive in normal cells). Such products should be radically cleaner, more precise therapies.